GoTo Telemed Launches AI-Powered Oral Cancer Screening Study to Address Late-Stage Diagnoses

KALISPELL, Mont. - July 1, 2026 - PRLog -- GoTo Telemed, a nationwide integrated telehealth ecosystem serving over 10 million patients, today announced a clinical study to validate a smartphone-based deep learning system for detecting oral potentially malignant disorders (OPMDs) and oral cancer in primary care, dental, and community health settings.

Oral cancer affects over 59,000 Americans annually, with nearly 13,000 deaths. Only one in four cases are caught early, when survival is 88%; late-stage survival drops to 37%.

"We are missing the window to catch oral cancer early," said a GoTo Telemed spokesperson. "This study will determine whether a smartphone AI system can match or exceed human diagnostic accuracy, potentially revolutionizing oral cancer screening."

Study Design: A three-arm randomized controlled trial (NCT06862414) enrolling 300–500 participants across multiple sites. Participants will be randomized to:

ArmIntervention

A   AI deep learning system (standalone screening)

B   Board‑certified dentist (AI not used)

C   Non‑certified health provider (AI not used)

Primary Outcomes: Sensitivity, specificity, and AUC for classifying lesions as benign, potentially malignant, or malignant.

Secondary Outcomes: Patient comfort and time efficiency.

Risk Factors: Smoking, betel nut chewing, and alcohol consumption will be recorded.

Recent AI models like DenseNet201 and MobileNet have achieved 84–95% accuracy on smartphone‑captured intraoral images. GoTo Telemed aims to establish a nationwide network of AI‑enabled screening sites for scalable early detection.

Media Contact:

GoTo Telemed Media Relations

info@gototelemed.com

(660) 628-1660

https://gototelemed.com/